TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

29 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

21 Jun 2024 17:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Jun 2024 15:10:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

30 May 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

17 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

13 May 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Leadership Changes

08 May 2024 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 May 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

29 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

10 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

14 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

11 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

27 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

07 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

07 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Feb 2024 15:05:00 By Nasdaq GlobeNewswire